Advisor Group Holdings, Inc. Immunic, Inc. Transaction History

Advisor Group Holdings, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.97 - $1.6 $1,067 - $1,760	-1,100 Reduced 62.43%	662 $0
Q3 2023 Nov 13, 2023	BUY	$1.35 - $2.87 $2,160 - $4,592	1,600 Added 987.65%	1,762 $2,000
Q2 2023 Aug 10, 2023	BUY	$1.33 - $2.51 $133 - $250	100 Added 161.29%	162 $0
Q1 2023 May 12, 2023	SELL	$1.35 - $2.87 $13 - $28	-10 Reduced 13.89%	62 $0
Q4 2022 Feb 10, 2023	BUY	$1.13 - $10.8 $81 - $777	72 New	72 $0
Q1 2022 May 04, 2022	SELL	$9.54 - $14.26 $2,385 - $3,565	-250 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$14.21 - $25.3 $56,626 - $100,820	-3,985 Reduced 94.1%	250 $4,000
Q4 2020 Feb 10, 2021	SELL	$14.8 - $20.37 $12,210 - $16,805	-825 Reduced 16.3%	4,235 $65,000
Q3 2020 Nov 12, 2020	BUY	$11.74 - $22.0 $59,404 - $111,320	5,060 New	5,060 $94,000

56.3M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $29.3M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.